The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD

Kirsten AM, Förster K, Radeczky E, Linnhoff A, Bálint Beatrix, Watz H, Wray H, Salkeld L, Cullberg M, Larsson B
2015